SCHEMBL16801121

SCHEMBL16801121

Cc1ccc2c(Br)ccc3oc4ccc(Br)c5ccc(C)c(c1c32)c45

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16800935 0.87 TSHR (0.44) ALDH1A1
SCHEMBL16801215 0.78
SCHEMBL10028230 0.76 AHR (0.31) ALDH1A1
SCHEMBL6808696 0.71 CYP1A2 (0.48) ALDH1A1
SCHEMBL16800979 0.71 CYP1A2 (0.40) NPC1RAB9AALDH1A1
SCHEMBL4695580 0.71 ALDH1A1 (0.38) ESR2NPC1ALDH1A1
SCHEMBL5251847 0.70 ALDH1A1 (0.42) NPC1ALDH1A1
SCHEMBL15497853 0.70 ALDH1A1 (0.61) ALDH1A1
SCHEMBL16801012 0.69 CYP1A1 (0.40) ESR2NPC1RAB9AALDH1A1
SCHEMBL17151500 0.68 ALDH1A1 (0.48) NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11917913-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2024-02-27 US disclosed
US-11917913-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2024-02-27 US disclosed
US-20190280218-A1 SUBSTITUTED OXEPINES MERCK PATENT GMBH (DE) 2019-09-12 US disclosed
US-10374170-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2019-08-06 US disclosed
US-20160308146-A1 SUBSTITUTED OXEPINES MERCK PATENT GMBH (DE) 2016-10-20 US disclosed
US-20160308146-A1 SUBSTITUTED OXEPINES MERCK PATENT GMBH (DE) 2016-10-20 US disclosed
WO-2015082046-A2 SUBSTITUTED OXEPINES MERCK PATENT GMBH (DE) 2015-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11917913-B2 Substituted oxepines OXGR1, OXTR, OCIAD2 ESR1 285/4885ESR2 497/4885NPC1 4330/4885
US-10374170-B2 Substituted oxepines OXGR1, OXTR, OCIAD2 ESR1 285/4885ESR2 497/4885NPC1 4330/4885
US-20190280218-A1 SUBSTITUTED OXEPINES OXGR1, OXTR, OCIAD2 ESR1 285/4885ESR2 497/4885NPC1 4330/4885
US-20160308146-A1 SUBSTITUTED OXEPINES OXGR1, OXTR, OCIAD2 ESR1 285/4885ESR2 497/4885NPC1 4330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.